Financhill
Sell
43

VRTX Quote, Financials, Valuation and Earnings

Last price:
$474.54
Seasonality move :
15.02%
Day range:
$473.64 - $499.07
52-week range:
$377.85 - $519.88
Dividend yield:
0%
P/E ratio:
26.10x
P/S ratio:
11.17x
P/B ratio:
7.43x
Volume:
2.9M
Avg. volume:
1.4M
1-year change:
17.48%
Market cap:
$121.9B
Revenue:
$11B
EPS (TTM):
-$2.20

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VRTX
Vertex Pharmaceuticals
$2.9B $4.31 5.83% 2.33% $497.84
AMGN
Amgen
$8.1B $4.28 5.75% 287.63% $316.10
BIIB
Biogen
$2.2B $3.62 -5.63% 2.56% $198.22
GILD
Gilead Sciences
$6.8B $1.75 -0.05% 49.96% $111.67
LLY
Eli Lilly and
$12.8B $4.69 25.94% 67.59% $1,010.47
MRNA
Moderna
$130.3M -$3.10 -19.37% -0.05% $52.35
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VRTX
Vertex Pharmaceuticals
$474.62 $497.84 $121.9B 26.10x $0.00 0% 11.17x
AMGN
Amgen
$294.39 $316.10 $158.1B 38.99x $2.38 3.1% 4.76x
BIIB
Biogen
$122.98 $198.22 $18B 10.99x $0.00 0% 1.86x
GILD
Gilead Sciences
$107.25 $111.67 $133.6B 289.86x $0.79 2.89% 4.69x
LLY
Eli Lilly and
$738.21 $1,010.47 $663B 63.04x $1.50 0.73% 14.82x
MRNA
Moderna
$25.11 $52.35 $9.7B -- $0.00 0% 3.05x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VRTX
Vertex Pharmaceuticals
-- 1.026 -- 2.17x
AMGN
Amgen
91.09% 0.284 43.85% 0.84x
BIIB
Biogen
27.36% 0.095 28.25% 0.77x
GILD
Gilead Sciences
58.02% 0.600 23.22% 1.33x
LLY
Eli Lilly and
70.33% 0.800 5.05% 0.59x
MRNA
Moderna
-- 0.004 -- 3.45x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VRTX
Vertex Pharmaceuticals
$2.5B $1.1B -3.23% -3.23% 39.12% $492M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
BIIB
Biogen
$1.9B $450.6M 7.33% 10.33% 14.32% $694.6M
GILD
Gilead Sciences
$6B $2.4B 1.09% 2.5% 31.92% $2.8B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
MRNA
Moderna
$217M -$1.2B -29.09% -29.09% -123.22% $303M

Vertex Pharmaceuticals vs. Competitors

  • Which has Higher Returns VRTX or AMGN?

    Amgen has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 6.9%. Vertex Pharmaceuticals's return on equity of -3.23% beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About VRTX or AMGN?

    Vertex Pharmaceuticals has a consensus price target of $497.84, signalling upside risk potential of 4.89%. On the other hand Amgen has an analysts' consensus of $316.10 which suggests that it could grow by 7.38%. Given that Amgen has higher upside potential than Vertex Pharmaceuticals, analysts believe Amgen is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    AMGN
    Amgen
    9 14 2
  • Is VRTX or AMGN More Risky?

    Vertex Pharmaceuticals has a beta of 0.504, which suggesting that the stock is 49.617% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.

  • Which is a Better Dividend Stock VRTX or AMGN?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.1% to investors and pays a quarterly dividend of $2.38 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios VRTX or AMGN?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are smaller than Amgen quarterly revenues of $9.1B. Vertex Pharmaceuticals's net income of $913M is higher than Amgen's net income of $627M. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Amgen's PE ratio is 38.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 11.17x versus 4.76x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    11.17x 26.10x $2.9B $913M
    AMGN
    Amgen
    4.76x 38.99x $9.1B $627M
  • Which has Higher Returns VRTX or BIIB?

    Biogen has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 10.87%. Vertex Pharmaceuticals's return on equity of -3.23% beat Biogen's return on equity of 10.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    BIIB
    Biogen
    76.23% $1.83 $23B
  • What do Analysts Say About VRTX or BIIB?

    Vertex Pharmaceuticals has a consensus price target of $497.84, signalling upside risk potential of 4.89%. On the other hand Biogen has an analysts' consensus of $198.22 which suggests that it could grow by 61.18%. Given that Biogen has higher upside potential than Vertex Pharmaceuticals, analysts believe Biogen is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    BIIB
    Biogen
    11 18 0
  • Is VRTX or BIIB More Risky?

    Vertex Pharmaceuticals has a beta of 0.504, which suggesting that the stock is 49.617% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

  • Which is a Better Dividend Stock VRTX or BIIB?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRTX or BIIB?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are larger than Biogen quarterly revenues of $2.5B. Vertex Pharmaceuticals's net income of $913M is higher than Biogen's net income of $266.7M. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Biogen's PE ratio is 10.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 11.17x versus 1.86x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    11.17x 26.10x $2.9B $913M
    BIIB
    Biogen
    1.86x 10.99x $2.5B $266.7M
  • Which has Higher Returns VRTX or GILD?

    Gilead Sciences has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 23.56%. Vertex Pharmaceuticals's return on equity of -3.23% beat Gilead Sciences's return on equity of 2.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    GILD
    Gilead Sciences
    79.11% $1.42 $46B
  • What do Analysts Say About VRTX or GILD?

    Vertex Pharmaceuticals has a consensus price target of $497.84, signalling upside risk potential of 4.89%. On the other hand Gilead Sciences has an analysts' consensus of $111.67 which suggests that it could grow by 4.12%. Given that Vertex Pharmaceuticals has higher upside potential than Gilead Sciences, analysts believe Vertex Pharmaceuticals is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    GILD
    Gilead Sciences
    15 11 0
  • Is VRTX or GILD More Risky?

    Vertex Pharmaceuticals has a beta of 0.504, which suggesting that the stock is 49.617% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

  • Which is a Better Dividend Stock VRTX or GILD?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.89% to investors and pays a quarterly dividend of $0.79 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

  • Which has Better Financial Ratios VRTX or GILD?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Vertex Pharmaceuticals's net income of $913M is lower than Gilead Sciences's net income of $1.8B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Gilead Sciences's PE ratio is 289.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 11.17x versus 4.69x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    11.17x 26.10x $2.9B $913M
    GILD
    Gilead Sciences
    4.69x 289.86x $7.6B $1.8B
  • Which has Higher Returns VRTX or LLY?

    Eli Lilly and has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 32.59%. Vertex Pharmaceuticals's return on equity of -3.23% beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About VRTX or LLY?

    Vertex Pharmaceuticals has a consensus price target of $497.84, signalling upside risk potential of 4.89%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 36.88%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    LLY
    Eli Lilly and
    16 4 0
  • Is VRTX or LLY More Risky?

    Vertex Pharmaceuticals has a beta of 0.504, which suggesting that the stock is 49.617% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

  • Which is a Better Dividend Stock VRTX or LLY?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios VRTX or LLY?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Vertex Pharmaceuticals's net income of $913M is lower than Eli Lilly and's net income of $4.4B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Eli Lilly and's PE ratio is 63.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 11.17x versus 14.82x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    11.17x 26.10x $2.9B $913M
    LLY
    Eli Lilly and
    14.82x 63.04x $13.5B $4.4B
  • Which has Higher Returns VRTX or MRNA?

    Moderna has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of -117.16%. Vertex Pharmaceuticals's return on equity of -3.23% beat Moderna's return on equity of -29.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    MRNA
    Moderna
    22.7% -$2.91 $10.9B
  • What do Analysts Say About VRTX or MRNA?

    Vertex Pharmaceuticals has a consensus price target of $497.84, signalling upside risk potential of 4.89%. On the other hand Moderna has an analysts' consensus of $52.35 which suggests that it could grow by 108.5%. Given that Moderna has higher upside potential than Vertex Pharmaceuticals, analysts believe Moderna is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    MRNA
    Moderna
    5 17 1
  • Is VRTX or MRNA More Risky?

    Vertex Pharmaceuticals has a beta of 0.504, which suggesting that the stock is 49.617% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

  • Which is a Better Dividend Stock VRTX or MRNA?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRTX or MRNA?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are larger than Moderna quarterly revenues of $956M. Vertex Pharmaceuticals's net income of $913M is higher than Moderna's net income of -$1.1B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 11.17x versus 3.05x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    11.17x 26.10x $2.9B $913M
    MRNA
    Moderna
    3.05x -- $956M -$1.1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Okta a Good Stock to Buy?
Is Okta a Good Stock to Buy?

Okta (NASDAQ:OKTA) is used by some of the largest firms…

Is Fidelity High Dividend ETF a Good Investment Now?
Is Fidelity High Dividend ETF a Good Investment Now?

Fidelity’s High Dividend ETF (FDVV) is a fund that offers…

Is Kinder Morgan Dividend Yield Worth It?
Is Kinder Morgan Dividend Yield Worth It?

Kinder Morgan (NYSE:KMI) is a major energy infrastructure company in…

Stock Ideas

Sell
37
Is AAPL Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 31x

Sell
37
Is MSFT Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 30x

Sell
31
Is NVDA Stock a Buy?

Market Cap: $2.3T
P/E Ratio: 32x

Alerts

Sell
45
RGC alert for Apr 5

Regencell Bioscience Holdings [RGC] is up 32.59% over the past day.

Sell
25
GDXU alert for Apr 5

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 27.33% over the past day.

Buy
76
SOXS alert for Apr 5

Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 23.96% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock